SCHEMBL18936355

SCHEMBL18936355

O=C(CCCOCc1ccccc1)c1ccccc1F

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.48
CTNNB1 P35222 2/20 0.48
WNT3A P56704 2/20 0.48
PTPN1 P18031 1/20 0.46
ERCC5 P28715 1/20 0.46
FEN1 P39748 1/20 0.46
ALDH1A1 P00352 2/20 0.46
FAAH O00519 1/20 0.43
RAB9A P51151 1/20 0.42
EPHX2 P34913 1/20 0.41
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
TSHR P16473 2/20 0.40
GPR52 Q9Y2T5 1/20 0.40
CYP3A4 P08684 1/20 0.40
MAPK1 P28482 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
TEAD3 Q99594 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18936242 0.91 NPC1 (0.50) NPC1CTNNB1WNT3APTPN1ERCC5
SCHEMBL7803908 0.86 GRM5 (0.45) ALDH1A1FAAHRAB9ACES2CES1
SCHEMBL15431705 0.81 NPC1 (0.52) NPC1CTNNB1WNT3APTPN1ERCC5
SCHEMBL18936367 0.81 CTNNB1 (0.49) CTNNB1WNT3APTPN1ERCC5FEN1
SCHEMBL14732971 0.80 CTNNB1 (0.61) NPC1CTNNB1WNT3APTPN1ERCC5
SCHEMBL6488590 0.80 TDP1 (0.61) NPC1ALDH1A1FAAHRAB9AEPHX2
SCHEMBL6383722 0.77 PTPN1 (0.58) CTNNB1WNT3APTPN1ERCC5FEN1
SCHEMBL291194 0.77 SMN1; SMN2 (0.57) ALDH1A1EPHX2TSHRMAPK1TEAD3
SCHEMBL20835784 0.76 BCHE (0.47) NPC1CTNNB1WNT3AFAAHRAB9A
SCHEMBL2079376 0.76 TSHR (0.50) ALDH1A1EPHX2TSHRTDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3383493-B1 CARBOCYCLIC FUSED IMINOTHIADIAZINE DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME (US) 2021-02-17 EP disclosed
US-10329291-B2 C5-C6-carbocyclic fused iminothiadiazine dioxides as BACE inhibitors, compositions, and their use MERCK SHARP & DOHME CORP. 2019-06-25 US disclosed
WO-2017095759-A1 C5-C6-CARBOCYCLIC FUSED IMINOTHIADIAZINE DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2017-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10329291-B2 C5-C6-carbocyclic fused iminothiadiazine dioxides as BACE inhibitors, compositions, and their use BACE1, BACE2, APP NPC1 554/4885CTNNB1 209/4885WNT3A 310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.